At a glance
- Originator GlaxoSmithKline
- Class Cytostatics
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Feb 1997 Discontinued-II for Cancer in United Kingdom (Unknown route)
- 08 May 1996 Phase-II clinical trials for Cancer in United Kingdom (Unknown route)
- 18 Jul 1995 Discontinued-I for Cancer in United Kingdom (Unknown route)